ERS Genomics was formed to commercialize the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner, and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use.
ERS Genomics was formed to commercialize the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner, and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use.
